Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment

Molecular Psychiatry, Published online: 18 October 2019; doi:10.1038/s41380-019-0540-zDruggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment

Source: Molecular Psychiatry - October 17, 2019 Category: Psychiatry Authors: Tor-Arne Hegvik Kai Wal øen Sunil K. Pandey Stephen V. Faraone Jan Haavik Tetyana Zayats Source Type: research